Welcome to Stempeutics

Stempeutics Research Bangalore is a late stage life science company focused on developing and commercializing novel therapeutics based on adult stem cells. It was founded by the Manipal Education and Medical Group in 2006. Stempeutics strength lies in developing innovative stem cell products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team.

Currently it is focusing on the following three innovative products: Stempeucel® drug, Stempeucare™ cosmetics and Stempeutron™ medical device.

In 2017, DCGI (Indian FDA) granted limited marketing approval of Stempeucel® product for the treatment of CLI patients due to Buerger's disease. It has received Form 46 and approval for the conduct of Phase 4 PMS study. Stempeucel® is the FIRST innovative stem cell based biological product to be approved by DCGI for limited sales. Stempeutics has also received label extension Phase 3 study approval for Atherosclerotic CLI.

Announcements

Company's flagship product is Stempeucel® drug. It is an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells derived from bone marrow of healthy, adult volunteers. Stempeucel® is being developed for the treatment of Critical Limb Ischemia (CLI) , Osteoarthritis (OA) & Diabetic Foot Ulcer (DFU). In 2017 DCGI granted manufacturing & marketing approval for Stempeucel® product for the treatment of CLI due to Buerger's disease patients. Stempeucel® is also ready for Phase 3 Atherosclerotic CLI, Phase 3 OA and Phase 2 DFU. Stempeucel® has strong patent protection with 18 patent applications filed across the globe. The core Stempeucel® patent has been granted in USA, China, UK, Germany, France, Italy, Australia, New Zealand, South Africa, Japan, and Singapore. Stempeucel® has been classified as an ATMP product by EMA and designated as an Orphan Drug for the treatment of CLI due to Buerger's Disease by EMA.

Another innovative product being developed by Stempeutics is Stempeucare® range of cosmetics. It is developed from adult human stem cells derived Growth Factors/Cytokines cocktail for various topical applications including rejuvenation of aging skin, hair fall control & hair growth, under eye cream etc. First product which is being marketed in India is Cutisera™. Cutisera™ is an intensive firming skin care cosmetic product with multiple benefits. Other products in the pipe line are (a) Trichosera for anti-hair fall and hair re-growth (b) Optisera - an eye care product for reducing eye bags & dark circles and fine lines & wrinkles. Stempeutics is looking for strong, strategic partner to market these innovative products developed from Growth Factors/Cytokines secreted by adult human stem cells.

It is an automated, point-of-care medical device for isolation of therapeutic stem and stromal cells from aspirated fat/adipose tissue. Adipose tissue stroma is a rich source of mesenchymal stem cells and endothelial progenitor cells, as well as other tissue-building cells such as vascular smooth muscle cells, pericytes, pre-adipocytes and fibroblasts. Stempeutron is under beta phase of development and Stempeutics is looking for strategic partner to complete the development and taking the device to the market.

US Patent Japan Patent India Bio